Neurocrine Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kyle W. Gano
- Full Time Employees
- 1,800
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12780 El Camino Real San Diego CA United States of America 92130
- IPO Date
- May 23, 1996
- CIK
- 0000914475
- Website
- neurocrine.com
- Similar Companies
- Business
- Neurocrine Biosciences, Inc. (NBIX) is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for neurological, neuroendocrine and neuropsychiatric disorders. Founded in 1992 and headquartered in San Diego, California, the company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved for tardive dyskinesia in adults and chorea associated with Huntington's disease; ONGENTYS (opicapone), a catechol-O-methyltransferase inhibitor licensed for Parkinson's disease; and partnered products including ORILISSA (elagolix) and ORIAHNN for endometriosis and uterine fibroids. Its pipeline features NBI-1117568, a muscarinic receptor agonist in Phase II for schizophrenia; osavampator (formerly NBI-1065845), an AMPA positive allosteric modulator for major depressive disorder; and preclinical NLRP3 inhibitors for neuroinflammation and immunology; the company operates primarily in the United States with global partnerships. Recent developments include a January 2025 amendment to its collaboration with Takeda, granting Neurocrine exclusive worldwide rights (except Japan) to osavampator following positive End-of-Phase 2 FDA feedback; a November 2025 global licensing agreement with Pharmaron (up to $881.5 million) and collaboration with TransThera Sciences for NLRP3 inhibitors outside Greater China; and strong third-quarter 2025 financial results with INGREZZA net sales of $687 million.
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
4basebio Announces Appointment of Chief Financial Officer and Board Changes
Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia